[Federal Register Volume 87, Number 233 (Tuesday, December 6, 2022)]
[Notices]
[Page 74648]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-26430]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: Use and 
Development of RAB13 and NET1 Targeting Antisense Oligonucleotides in 
the Treatment of Cancer

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an Exclusive Patent License to practice the 
inventions embodied in the U.S. Patents and Patent Applications listed 
in the Supplementary Information section of this notice to Drug 
Development and Filing Consulting, LLC located in Maryland, USA.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before December 21, 2022 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated an Exclusive Patent License 
should be directed to: Suna Gulay French, Technology Transfer Manager, 
Telephone: (240)-276-7424; Email: [email protected].

SUPPLEMENTARY INFORMATION: 

Intellectual Property

    1. United States Provisional Patent Application No. 62/966,204, 
filed January 27, 2020 and entitled ``RAB13 and NET1 Antisense 
Oligonucleotides to Treat Metastatic Cancer'' [HHS Ref. No. E-041-2020-
0-US-01];
    2. PCT Patent Application No. PCT/US2021/015053, filed January 26, 
2021 and entitled ``RAB13 and NET1 Antisense Oligonucleotides to Treat 
Metastatic Cancer'' [HHS Ref. No. E-041-2020-0-PCT-02]; and
    3. United States Patent Application No. 17/792,507, filed July 13, 
2022 and entitled ``Antisense Oligos that Block Cancer Cell Migration 
and Invasion'' [HHS Ref. No. E-041-2020-0-US-03].
    The patent rights in these inventions have been assigned and/or 
exclusively licensed to the government of the United States of America.
    The prospective exclusive license territory may be the United 
States only and the field of use may be limited to: ``Use and 
development of RAB13 and NET1 targeting antisense oligonucleotides in 
treatment of breast cancer, ovarian cancer, cervical cancer and head 
and neck cancer in humans.''
    This technology discloses RAB13 and NET1 targeting antisense 
oligonucleotides (ASOs) for use in targeted cancer therapy. These ASOs 
bind to the 3'-untranslated regions of RAB13 and NET1 mRNAs and prevent 
the localization of these mRNAs to cellular protrusions involved in 
motility. These ASOs reduce cell motility and migration in vitro. Due 
to this reduction in cell motility and migration, these ASOs are 
expected to have uses in the treatment of metastatic cancers.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the National 
Cancer Institute receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially, and may be 
made publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information in these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: November 30, 2022.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2022-26430 Filed 12-5-22; 8:45 am]
BILLING CODE 4140-01-P